Profile data is unavailable for this security.
About the company
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
- Revenue in USD (TTM)0.00
- Net income in USD-182.39m
- Incorporated2000
- Employees251.00
- LocationXenon Pharmaceuticals Inc3650 Gilmore WayVANCOUVER V5G 4W8CanadaCAN
- Phone+1 (604) 484-3300
- Fax+1 (604) 484-3450
- Websitehttps://www.xenon-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 2.79bn | 497.00 | -- | 7.73 | -- | 11.20 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Arcellx Inc | 110.32m | -70.69m | 2.90bn | 130.00 | -- | 5.86 | -- | 26.30 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.91bn | 91.00 | -- | 6.33 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Ideaya Biosciences Inc | 23.38m | -112.96m | 2.91bn | 124.00 | -- | 4.09 | -- | 124.42 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Azenta Inc | 641.02m | -17.37m | 2.93bn | 3.50k | -- | 1.20 | 41.92 | 4.57 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 2.95bn | 525.00 | -- | 15.94 | -- | 16.21 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.10bn | 251.00 | -- | 3.34 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.16bn | 517.00 | -- | 19.63 | -- | 7.92 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| SpringWorks Therapeutics Inc | 5.45m | -325.10m | 3.26bn | 305.00 | -- | 5.16 | -- | 598.24 | -5.14 | -5.14 | 0.0862 | 8.52 | 0.008 | -- | -- | 17,859.02 | -47.95 | -36.97 | -53.00 | -39.49 | 92.25 | -- | -5,968.50 | -2,176.46 | 6.37 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| 10X Genomics Inc | 618.73m | -255.10m | 3.29bn | 1.26k | -- | 4.43 | -- | 5.31 | -2.18 | -2.18 | 5.28 | 6.22 | 0.6206 | 2.70 | 5.65 | 491,443.20 | -25.59 | -25.52 | -29.39 | -29.05 | 66.15 | 75.88 | -41.23 | -48.53 | 4.11 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.30bn | 18.00k | -- | 1.89 | 35.50 | 1.06 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Iovance Biotherapeutics Inc | 1.19m | -444.04m | 3.31bn | 557.00 | -- | 5.20 | -- | 2,786.02 | -1.89 | -1.89 | 0.0051 | 2.28 | 0.0017 | -- | -- | 2,134.65 | -61.49 | -51.47 | -71.47 | -57.56 | -804.54 | -- | -37,345.42 | -137,873.80 | 2.70 | -- | 0.0017 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.38bn | 271.00 | 24.27 | 2.05 | 20.88 | 2.67 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
Data as of Apr 24 2024. Currency figures normalised to Xenon Pharmaceuticals Inc's reporting currency: US Dollar USD
44.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 5.67m | 7.51% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.85m | 6.44% |
| Driehaus Capital Management LLCas of 31 Dec 2023 | 4.35m | 5.76% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 4.16m | 5.52% |
| Polar Capital LLPas of 31 Dec 2023 | 3.07m | 4.07% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 2.68m | 3.56% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 2.46m | 3.26% |
| Commodore Capital LPas of 31 Dec 2023 | 2.17m | 2.87% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 2.13m | 2.82% |
| Pictet Asset Management SAas of 31 Dec 2023 | 2.04m | 2.71% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
